Aroa Biosurgery: A Breakout Year for ASX Small-Cap
Aroa Biosurgery (ASX: ARX) is experiencing a significant breakout year, positioning itself as a key player in the complex wound care and soft tissue reconstruction sector. As a commercial-stage medical device company, Aroa specializes in biologic medical devices through its AROA-ECM (Extracellular Matrix) platform. The company has been attracting attention from analysts and investors alike, with Bell Potter highlighting strong growth potential based on its FY26 results.
Strong Financial Performance in FY26
In its latest financial report for FY26, Aroa delivered impressive results that exceeded expectations. The company reported total revenue of NZ$104 million, surpassing its guidance range of NZ$92 to NZ$100 million. This represents a 23% increase compared to FY25. Additionally, the company achieved a normalised EBITDA of NZ$13 million, which was well above its guidance of NZ$5 to NZ$8 million.
Operating cash flow also saw a significant improvement, reaching NZ$10.5 million, an increase of NZ$13.1 million from FY25. The Myriad product line contributed NZ$49.5 million in revenue, marking a 54% growth compared to the previous fiscal year.
Outlook for FY27
Looking ahead to FY27, Aroa has set ambitious targets, expecting total revenue of between NZ$115 million and NZ$125 million. This would represent a 13-23% constant-currency growth rate. Direct sales are anticipated to grow by 24-40%, driven by continued momentum in the Myriad product line and the launch of Symphony.
Managing Director and CEO Brian Ward commented on the company’s outlook, stating:
“FY26 was a successful year for Aroa. Revenue grew 23% to NZ$103.9 million, driven by 54% growth in the Myriad portfolio, which was achieved with the same number of salespeople as the previous year, demonstrating strong operating leverage in the business.”
He added that the company expects Myriad momentum to continue, supported by deeper account penetration and higher productivity across the US direct sales team. Symphony’s value proposition aligns well with the changing reimbursement environment, and the company believes it can become an important medium-term growth catalyst.
Bell Potter’s Perspective
Following these results, Bell Potter has updated its guidance for Aroa. The broker highlighted that Aroa delivered a very strong FY26 result, mainly driven by rapid growth in Myriad sales. They view this product as the core engine of the business and believe it can continue to grow at a solid double-digit rate due to its early stage in a large addressable market.
Bell Potter also noted that Aroa is successfully transitioning toward a more scalable business model by expanding its direct sales force. This shift reduces reliance on its US distribution partner and supports more consistent revenue growth moving forward.
However, the broker anticipates higher costs in the near term as the company invests more heavily in sales, marketing, and hiring to support growth. This has led them to slightly lower their profit (EBITDA) forecasts, even though they are not significantly changing their revenue expectations.
Potential Upside for Investors
Based on this guidance, Bell Potter has set an updated price target of $1.09 for Aroa Biosurgery. From yesterday’s closing price of 62 cents per share, this indicates an upside potential of over 75%.
Investors considering whether to invest $1,000 in Aroa Biosurgery should take into account expert insights. Motley Fool investing expert Scott Phillips recently highlighted what he believes are the 5 best stocks for investors to buy right now, and Aroa Biosurgery was not among them.
While Aroa shows strong potential, it is essential for investors to conduct thorough research and consider their own financial goals before making any investment decisions.
Additional Reading
For those interested in exploring other ASX small-cap opportunities, there are several articles worth reading. These include discussions on whether certain ASX small caps are too cheap to ignore and how specific healthcare shares are performing in the current market.
The Motley Fool Australia’s parent company, Motley Fool Holdings Inc., has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
